Anti-amyloid medicines
From failed or withdrawn antibodies to two US-approved early-stage products, with access and ARIA still open.
Overview
This roadmap is a teaching timeline for the Alzheimer’s antibody story on this atlas. It is not a prediction that more antibodies will help more stages.
- 2016-2019historic
Large antibody failures
EXPEDITION 3 and ENGAGE show that amyloid lowering is not automatically clinical benefit.
- 2021-2024current
Approvals and a withdrawal
Aducanumab is authorised then withdrawn. Lecanemab and donanemab reach US labels for early disease.
- 2025-emerging
Access, mixed disease, next targets
Who is treated, who is monitored, and whether tau or blood-first triage changes the funnel.
Story
topLarge antibody failures
EXPEDITION 3 and ENGAGE show that amyloid lowering is not automatically clinical benefit.
EXPEDITION 3 tested solanezumab in mild Alzheimer’s disease and did not meet its primary endpoint. It is included as a negative amyloid-antibody result.
ENGAGE was a phase 3 aducanumab trial that did not meet its primary endpoint as designed. It is here as a failure, not as support for using the drug.
Approvals and a withdrawal
Aducanumab is authorised then withdrawn. Lecanemab and donanemab reach US labels for early disease.
Aducanumab was an amyloid antibody whose US Alzheimer’s indication was later withdrawn. It is historical context, not a current option.
Lecanemab is an infused antibody for early Alzheimer’s disease after amyloid is confirmed. It can cause brain swelling or bleeding on MRI and is not a cure.
Donanemab is a monthly infused antibody for early Alzheimer’s disease after amyloid confirmation, with the same ARIA monitoring theme as other amyloid antibodies.
Access, mixed disease, next targets
Who is treated, who is monitored, and whether tau or blood-first triage changes the funnel.
Similar pages
not linked directly; found by shared links- CompanyEli Lilly
Shares EXPEDITION 3, Remternetug, Donanemab, Alzheimer’s disease and the tag dementia-atlas.
- TechnologyAnti-amyloid antibodies
Shares Aducanumab, Donanemab, Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- CompanyBiogen
Shares ENGAGE, Aducanumab, Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- TargetAmyloid-beta
Shares Remternetug, Donanemab, Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- DiagnosisMild cognitive impairment
Shares Blood test before PET or lumbar puncture, Donanemab, Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- TechnologyApoE testing
Shares Donanemab, Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- TermARIA
Shares Donanemab, Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- IdeaAntibody trials that enrol mixed and comorbid disease
Shares Donanemab, Lecanemab, Alzheimer’s disease and the tag dementia-atlas.